Compare KSS & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSS | PRCT |
|---|---|---|
| Founded | 1962 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1992 | 2021 |
| Metric | KSS | PRCT |
|---|---|---|
| Price | $17.69 | $27.25 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $16.08 | ★ $51.13 |
| AVG Volume (30 Days) | ★ 3.6M | 1.1M |
| Earning Date | 03-10-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $15,751,000,000.00 | $299,907,000.00 |
| Revenue This Year | N/A | $48.30 |
| Revenue Next Year | N/A | $29.44 |
| P/E Ratio | $10.24 | ★ N/A |
| Revenue Growth | N/A | ★ 50.07 |
| 52 Week Low | $6.04 | $27.23 |
| 52 Week High | $25.22 | $75.29 |
| Indicator | KSS | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 32.26 |
| Support Level | $17.31 | $28.76 |
| Resistance Level | $18.82 | $29.94 |
| Average True Range (ATR) | 0.77 | 1.46 |
| MACD | 0.11 | -0.23 |
| Stochastic Oscillator | 70.85 | 0.00 |
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.